AEON logo

AEON BIOPHARMA INC

AEONNYSE AMERICAN
🏆 #4944 by market capEarnings Nov 13US Equity
$0.26▼ $0.00 (−0.19%)
After hours · at close
🔔
Track AEON
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.2%
7d▲ 1.1%
14d▼ 0.2%
30d▼ 14.5%
ytd▼ 77.8%
1y▼ 66.9%
🏦Market Cap
$12M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
64
Fair

Trading Snapshot

Day Range
$0.26 – $0.27
52-Week Range
$0.18 – $1.45
Volume
$2.79B
Avg Volume
$2.30B
Shares Outstanding
44.2M
Next Earnings
Dec 2, 2026

Fundamentals Snapshot

Annual Revenue
$2M
Last Q Revenue
$474,112
P/E Ratio
-0.1
P/S Ratio
0.0x
EPS (TTM)
$-1.08
Dividend Yield
0.00%
Dilution (1yr)
+2079.9%

Why Investors Own AEON

  • ✓High-growth profile — revenue up +57.0% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 33% gross margin and 18% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

AEON logo

AEON BIOPHARMA INC

AEON
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$13M▼ −117.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$17M▼ −14.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
12.1M▲ +2079.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$33M▼ −$20M YoY
StockOtter · stockotter.space

About AEON BIOPHARMA INC

AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Ratings

ⓘ
Consensus
Buy
9 analysts
Strong Buy2
Buy6
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
CNBC·2h ago

AEON BIOPHARMA INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift AEON price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

AEON BIOPHARMA INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.